Literature DB >> 9581697

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

A Kasahara1, N Hayashi, K Mochizuki, M Takayanagi, K Yoshioka, S Kakumu, A Iijima, A Urushihara, K Kiyosawa, M Okuda, K Hino, K Okita.   

Abstract

To elucidate the risk factors for liver carcinogenesis and to examine the incidence of hepatocellular carcinoma (HCC) after interferon therapy, 1,022 chronic hepatitis C patients treated with interferon were followed by ultrasonography for 13 to 97 months (median 36 months). Sustained response with prolonged alanine aminotransferase normalization was found in 313 patients, transient response with alanine aminotransferase relapse after therapy in 304, and no response in 405. Forty-six developed HCC, of whom 5 were sustained responders, 9 were transient responders, and 32 were nonresponders. The cumulative incidence of HCC in transient responders was almost equal to that in sustained responders, and it was significantly higher in nonresponders than in sustained and transient responders (P=.0009). The seventh-year cumulative incidence rates of HCC in sustained responders, transient responders, and nonresponders were estimated to be 4.3%, 4.7%, and 26.1%, respectively. However, there was no significant difference in the cumulative incidence of HCC between patients with HCV subtype 1 and 2 (P=.14). Cox regression analysis showed that the risk of HCC development was not elevated in transient responders compared with sustained responders, but that the risk was 7.90-fold higher in nonresponders than in sustained responders (P=.008). Patients > or =55 years of age had a significantly higher risk ratio (4.65) than did those under 55 years of age (P=.006). The risk of HCC development in men was 4.35 times higher than the risk in women (P=.02). However, the degree of fibrosis was not a significant risk factor for the development of HCC (risk ratio, 3.16; P=.052). These results suggest that patients in the high-risk group of HCC after interferon therapy were those who showed no response, those who were older, and those who were male, and that such patients should be carefully followed using ultrasonography.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9581697     DOI: 10.1002/hep.510270529

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  97 in total

Review 1.  Hepatitis C and liver transplantation.

Authors:  M Berenguer; T L Wright
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

2.  Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis.

Authors:  C Chapoutot; M Esslimani; Z Joomaye; J Ramos; P Perney; C Laurent; P Fabbro-Peray; D Larrey; J Domergue; F Blanc
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

3.  Interferon therapy reduces the risk for hepatocellular carcinoma.

Authors:  J L Brown
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

4.  Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Authors:  Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; Hitoshi Asakura; Akira Naito; Shigeki Mori; Kojiro Hata; Kentaro Igarashi; Hidenori Hara; Hironobu Ohta; Kenji Soga; Toshiaki Watanabe; Tomoteru Kamimura
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

5.  Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.

Authors:  Helen S Yee; Sue L Currie; Kathryn Tortorice; Myrna Cozen; Hui Shen; Summer Chapman; Fran Cunningham; Alexander Monto
Journal:  Dig Dis Sci       Date:  2011-06-02       Impact factor: 3.199

6.  Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

Authors:  María Trapero-Marugán; Jorge Mendoza; María Chaparro; Leticia González-Moreno; José Andrés Moreno-Monteagudo; María Jesús Borque; Ricardo Moreno-Otero
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 7.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

8.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

9.  Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.

Authors:  Yasuto Takeuchi; Fusao Ikeda; Toshiya Osawa; Yasuyuki Araki; Kouichi Takaguchi; Youichi Morimoto; Noriaki Hashimoto; Kousaku Sakaguchi; Tatsuro Sakata; Masaharu Ando; Yasuhiro Makino; Shuji Matsumura; Hiroki Takayama; Hiroyuki Seki; Shintarou Nanba; Yuki Moritou; Tetsuya Yasunaka; Hideki Ohnishi; Akinobu Takaki; Kazuhiro Nouso; Yoshiaki Iwasaki; Kazuhide Yamamoto
Journal:  World J Hepatol       Date:  2015-09-08

10.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.